Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Century Therapeutics (IPSC) Income from Continuing Operations (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Income from Continuing Operations for 4 consecutive years, with 34422000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Income from Continuing Operations fell 10.24% to 34422000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 25606000.0, a 80.29% increase, with the full-year FY2024 number at 125697000.0, up 8.03% from a year prior.
  • Income from Continuing Operations was 34422000.0 for Q3 2025 at Century Therapeutics, down from 32541000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 76560000.0 in Q1 2025 to a low of 39398000.0 in Q4 2023.
  • A 4-year average of 25580066.67 and a median of 31677000.0 in 2022 define the central range for Income from Continuing Operations.
  • Peak YoY movement for Income from Continuing Operations: decreased 24.37% in 2023, then soared 372.82% in 2025.
  • Century Therapeutics' Income from Continuing Operations stood at 31677000.0 in 2022, then dropped by 24.37% to 39398000.0 in 2023, then increased by 10.65% to 35203000.0 in 2024, then rose by 2.22% to 34422000.0 in 2025.
  • Per Business Quant, the three most recent readings for IPSC's Income from Continuing Operations are 34422000.0 (Q3 2025), 32541000.0 (Q2 2025), and 76560000.0 (Q1 2025).